Delivery of oleic acid to the distal bowel might counteract sympathetic activation associated with bariatric surgery or the effects of GLP-1 analogues on increasing the ileal brake, thus potentially reducing the retardation of proximal gastrointestinal motility and inhibition of secretions seen after obesity treatments. The gene discussed is GCG; the disease is obesity disorder.